CONTRIBUTION OF BIOREGULATIONAL THERAPY IN TREATMENT OF MUSCULOSKELETAL SYSTEM DISORDERS. RESOLUTION OF THE RESULTS OF 01.03.2019 MEETING

Cover Page

Cite item

Full Text

Abstract

The article discusses the results of the meeting dedicated to bioregulational therapy and its contribution to treatment of patients with various disorders including musculoskeletal system disorders. Inconsistency between evolution of defense mechanisms and environment changes was a prerequisite for appearance, development and introduction of bioregulational therapy in clinical practice. It is evident that increase in life expectancy results in increase of prevalence of chronic disorders, in the first place such as obesity, hypertension, type II diabetes mellitus, cancer, and musculoskeletal system disorders. Increase in number of comorbidities is a limitation of counterindication for the use of traditional medications for pain and inflammation treatment, in particular non-steroid anti-inflammatory drugs. Taking into account high prevalence of musculoskeletal system disorders the rationale of bioregulational treatment and use of bioregulational medications with multiple effects with high safety profile are essential components of patients’ management. The article discusses evidence of effectiveness and safety of polycomponent herbal medications Traumeel® S and Zeel® T, opportunities of their use in complex treatment of pain and inflammation in acute and chronic musculoskeletal system disorders

About the authors

Irina S. Dydykina

Nasonova Research Institute of Rheumatology

Email: dydykina_is@mail.ru
канд. мед. наук, вед. науч. сотр. лаб. мониторинга безопасности антиревматических препаратов ФГБНУ «НИИР им. В.А. Насоновой» Москва, Россия

Evgenii G. Zotkin

Nasonova Research Institute of Rheumatology

д-р мед. наук, первый зам. дир. ФГБНУ «НИИР им. В.А. Насоновой» Москва, Россия

Polina S. Kovalenko

Nasonova Research Institute of Rheumatology

канд. мед. наук, мл. науч. сотр. отд. метаболических заболеваний костей и суставов с центром профилактики остеопороза Минздрава России ФГБНУ «НИИР им. В.А. Насоновой». Москва, Россия

References

  1. Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell 2015; 160 (5): 816-27.
  2. Scrivo R et al. Inflammation as "common soil" of the multifactorial diseases. Autoimmun Rev. 2011; 10 (7): 369-374.
  3. Libby P Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007; 65 (12 Pt 2): S140-S146.
  4. Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol 2012; 22 (17): R733-R740.
  5. Эрдес Ш.Ф., Дубинина Т.В., Г алушко Е.А. Боли в нижней части спины в общеклинической практике. Терапевтический архив. 2008; 80 (5): 59-61. [Erdes Sh.F., Dubinina T.V., Galushko E.A. Boli v nizhnei chasti spiny v obshcheklinicheskoi prakti-ke. Therapeutic Archive. 2008; 80 (5): 59-61 (in Russian).]
  6. Friedly J, Standaert C, Chan L. Epidemiology of spine care: the back pain dilemma. Phys Med Rehabil Clin N Am 2010; 21 (4): 659-77. doi: 10.1016/j.pmr.2010.08.00
  7. Litwic A, Edwards M, Dennison E, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull 2013; 105: 185-99. doi: 10.1093/bmb/lds038 15
  8. Zhang Y, Jordan J. Epidemiology of osteoarthritis. Clin Geriatr Med 2010; 26 (3): 355-69. doi: 10.1016/j.cger.2010.03.001
  9. Murphy L, Helmick C. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs 2012; 112 (3 Suppl. 1): 13-9. doi: 10.1097/01.NAJ.0000412646.80054.21
  10. Millar NL, Murrell GA, McInnes IB. Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatology (Oxford) 2013; 52 (5): 769-79. doi: 10.1093/rheumatology/kes409
  11. Яхно Н.Н., Кукушкин М.Л. Боль (практическое руководство для врачей). М.: Изд-во РАМН, 2012. [Iakhno N.N., Kukushkin M.L. Pain (a practical guide for doctors). Moscow: Izd-vo RAMN, 2012 (in Russian).]
  12. Кукушкин М.Л., Табеева Г.Р., Подчуфарова Е.В. Болевой синдром: патофизиология, клиника, лечение. М.: ИМА-пресс, 2011. [Kukushkin M.L., Tabeeva G.R., Podchufarova E.V. Pain syndrome: pathophysiology, clinic, treatment. Moscow: IMA-press, 2011 (in Russian).]
  13. Диагностика и лечение боли. Под ред. Дж.Х.Ван Роенн, Дж.А.Пэйс, М.И.Преодер. М.: Бином, 2012. [Diagnosis and treatment of pain. Pod red. Dzh.Kh.Van Roenn, Dzh.A.Peis, M.I.Preoder. Moscow: Binom, 2012 (in Russian).]
  14. http: //www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/ demography/
  15. Распоряжение Правительства Российской Федерации от 05.02.2016 №164-р «Стратегия действий в интересах граждан старшего поколения в Российской Федерации до 2025 года». [Rasporiazhenie Pravitel 'stva Rossiiskoi Federatsii ot 05.02.2016 №164-r "Strategiia deistvii v inte-resakh grazhdan starshego pokoleniia v Rossiiskoi Federatsii do 2025 goda" (in Russian).]
  16. https: //oarsi.org/research/standardization-osteoarthritis-definitions/
  17. Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Науч.-практ. ревматология. 2008; 4. [Folomeeva O.M., Galushko E.A., Erdes Sh.F. Rasprostranennost' revmaticheskikh zabolevanii v populiatsiiakh vzroslogo naseleniia Rossii i SShA. Nauch.-prakt. revmatologiia. 2008; 4 (in Russian).]
  18. Балабанова Р.М., Дубинина Т.В., Демина А.Б., Кричевская О.А. Заболеваемость болезнями костно-мышечной системы в Российской Федерации в 2015-2016 гг. Науч.-практ. ревматология. 2018; 56 (1): 15-21. [Balabanova R.M., Dubinina T.V., Demina A.B., Krichevskaia O.A. Zabolevaemost' bolezniami kostno-myshechnoi sistemy v Rossiiskoi Federatsii v 2015-2016 gg. Nauch.-prakt. revmatologiia. 2018; 56 (1): 15-21 (in Russian).]
  19. Казюлин А.Н., Гончаренко А.Ю., Маев И.В. Использование ребамипида в качестве гастро-протективного и противовоспалительного препарата при НПВП-гастропатиях. Лечебное дело. 2016;3: 50-9. [Kaziulin A.N., Goncharenko A.Iu., Maev I.V. Ispol'zovanie rebamipida v kachestve gastroprotektiv-nogo i protivovospalitel'nogo preparata pri NPVP-gastropatiiakh. Lechebnoe delo. 2016; 3: 50-9 (in Russian).]
  20. Bruyere O, Cooper C, Pelletier J et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; p. 2-11. doi: 10.1016/j.semarthri t.2014.05.014
  21. Castellsague J, Riera-Guardia N, Calingaert B et al; on behalf of the investigators of the Safety of Non-Steroidal Anti-inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications. A systematic review and meta-analysis of observational studies (the SOS Project). Drug Saf 2012; 35: 1127-45.
  22. Barkin RL, Beckerman M, Blum SL et al. Should nonsteroidal antiinflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010; 27: 775-89.
  23. Evans JM, McMahon AD, McGilchrist MM et al. Topical non-steroidal antiinflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage casecontrol study. BMJ 1995; 311: 22-6. ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS
  24. Antman EM, Bennett JS, Daugherty A et al; for the American Heart Association. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115: 1634-42.
  25. Schneider C. Traumeel - an emerging option to nonsteroidal anti-inflammatory drugs in the management of acute musculoskeletal injuries. Int J Gen Med 2011; 4: 225-34.
  26. Lussignoli S, Bertani S, Metelmann H et al. A homeopathic formulation, on blood-induced inflammation in rats. Complement Ther Med 1999; 7: 225-30.
  27. Gonzalez de Vega C, Speed C, Wolfarth B et al. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract 2013; 67: 979-89.
  28. Bohmer D, Ambrus P Treatment of sports injuries with Traumeel ointment: a controlled doubleblind study. Biol Ther 1992; 10: 290-300.
  29. Thiel W, Borho B. Posttraumatische Kniegelenksergusse und intra-artikulare Traumeel Injektion. Orthopadische Praxis 1991; 11: 721-5.
  30. Orizola AJ, Vargas F. The efficacy of Traumeel S versus diclofenac and placebo ointment in tendinous pain in elite athletes: a randomized controlled trial. Med Sci Sports Med Exerc 2007; 39 (Suppl. 5): S79, abstract 858.
  31. Gonzalez de Vega C, Speed C, Wolfarth B et al. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract 2013; 67: 979-89.
  32. Wolfarth B, Gonzalez de Vega C. Make an impact on your daily practice: the potential role for a natural multi-target medication. Curr Med Res Opin 2013.29 (Suppl. 2): 15-9.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies